Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

IL12A, MPHOSPH9/CDK2AP1 and RGS1 are novel multiple sclerosis susceptibility loci.
Relationship between NMO-antibody and anti-MOG antibody in optic neuritis.
Paraoxonase 1 activity in multiple sclerosis patients during mitoxantrone therapy.
RTL therapy for multiple sclerosis: a Phase I clinical study.
Novantrone (mitoxantrone HCl) Injection February 2009
Breastfeeding and multiple sclerosis.
Immune competence after alemtuzumab treatment of multiple sclerosis.
Teva Announces U.S. Supreme Court Decision to Reverse Federal Circuit Court’s Judgment on COPAXONE® 20 mg/mL Case and Remand for Further Review
One can prevent post-partum MS relapses by exclusive breast feeding: no.
Adaptive myelination from fish to man.
Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial.
Genmab announces results of ofatumumab Phase II study in multiple sclerosis
Immune mechanisms of new therapeutic strategies in multiple sclerosis-A focus on alemtuzumab.
Monocytes P2X7 purinergic receptor is modulated by glatiramer acetate in multiple sclerosis.
Glatiramer acetate after mitoxantrone induction improves MRI markers of lesion volume and permanent tissue injury in MS.
Santhera's Phase III program with Catena®/Raxone® in Duchenne muscular dystrophy on track to deliver pivotal data early in 2Q 2014
A G protein-coupled receptor is essential for Schwann cells to initiate myelination.
Treatment of neurological injury with thymosin β4.
Combination therapy with mitoxantrone and plasma exchange in aggressive relapsing remitting multiple sclerosis: A preliminary clinical study.
Architecture of human mTOR complex 1.
Biogen Idec submits application to FDA for approval of PLEGRIDY™ (peginterferon beta-1a) in multiple sclerosis
Rituximab versus fingolimod after natalizumab in multiple sclerosis patients.
Useful Links
Results of Phase III BRAVO Trial Reinforce Unique Profile of Laquinimod for Multiple Sclerosis Treatment
UCSF Seminar: "Antibody Repertoire Sequencing"

Pages